Tags

Type your tag names separated by a space and hit enter

Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro.
Br J Pharmacol. 2012 Apr; 165(8):2584-97.BJ

Abstract

BACKGROUND AND PURPOSE

Both CB(1) and CB(2) cannabinoid receptors have been shown to play a role in bone metabolism. Crucially, previous studies have focussed on the effects of cannabinoid ligands in murine bone cells. This study aimed to investigate the effects of cannabinoids on human bone cells in vitro.

EXPERIMENTAL APPROACH

Quantitative RT-PCR was used to determine expression of cannabinoid receptors and liquid chromatography-electrospray ionization tandem mass spectrometry was used to determine the presence of endocannabinoids in human bone cells. The effect of cannabinoids on human osteoclast formation, polarization and resorption was determined by assessing the number of cells expressing α(v) β(3) or with F-actin rings, or measurement of resorption area.

KEY RESULTS

Human osteoclasts express both CB(1) and CB(2) receptors. CB(2) expression was significantly higher in human monocytes compared to differentiated osteoclasts. Furthermore, the differentiation of human osteoclasts from monocytes was associated with a reduction in 2-AG levels and an increase in anandamide (AEA) levels. Treatment of osteoclasts with LPS significantly increased levels of AEA. Nanomolar concentrations of AEA and the synthetic agonists CP 55 940 and JWH015 stimulated human osteoclast polarization and resorption; these effects were attenuated in the presence of CB(1) and/or CB(2) antagonists.

CONCLUSIONS

AND IMPLICATIONS Low concentrations of cannabinoids activate human osteoclasts in vitro. There is a dynamic regulation of the expression of the CB(2) receptor and the production of the endocannabinoids during the differentiation of human bone cells. These data suggest that small molecules modulating the endocannabinoid system could be important therapeutics in human bone disease.

LINKED ARTICLES

This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7.

Authors+Show Affiliations

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. l.whyte@abdn.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21649637

Citation

Whyte, L S., et al. "Cannabinoids and Bone: Endocannabinoids Modulate Human Osteoclast Function in Vitro." British Journal of Pharmacology, vol. 165, no. 8, 2012, pp. 2584-97.
Whyte LS, Ford L, Ridge SA, et al. Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol. 2012;165(8):2584-97.
Whyte, L. S., Ford, L., Ridge, S. A., Cameron, G. A., Rogers, M. J., & Ross, R. A. (2012). Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. British Journal of Pharmacology, 165(8), 2584-97. https://doi.org/10.1111/j.1476-5381.2011.01519.x
Whyte LS, et al. Cannabinoids and Bone: Endocannabinoids Modulate Human Osteoclast Function in Vitro. Br J Pharmacol. 2012;165(8):2584-97. PubMed PMID: 21649637.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. AU - Whyte,L S, AU - Ford,L, AU - Ridge,S A, AU - Cameron,G A, AU - Rogers,M J, AU - Ross,R A, PY - 2011/6/9/entrez PY - 2011/6/9/pubmed PY - 2012/7/28/medline SP - 2584 EP - 97 JF - British journal of pharmacology JO - Br J Pharmacol VL - 165 IS - 8 N2 - BACKGROUND AND PURPOSE: Both CB(1) and CB(2) cannabinoid receptors have been shown to play a role in bone metabolism. Crucially, previous studies have focussed on the effects of cannabinoid ligands in murine bone cells. This study aimed to investigate the effects of cannabinoids on human bone cells in vitro. EXPERIMENTAL APPROACH: Quantitative RT-PCR was used to determine expression of cannabinoid receptors and liquid chromatography-electrospray ionization tandem mass spectrometry was used to determine the presence of endocannabinoids in human bone cells. The effect of cannabinoids on human osteoclast formation, polarization and resorption was determined by assessing the number of cells expressing α(v) β(3) or with F-actin rings, or measurement of resorption area. KEY RESULTS: Human osteoclasts express both CB(1) and CB(2) receptors. CB(2) expression was significantly higher in human monocytes compared to differentiated osteoclasts. Furthermore, the differentiation of human osteoclasts from monocytes was associated with a reduction in 2-AG levels and an increase in anandamide (AEA) levels. Treatment of osteoclasts with LPS significantly increased levels of AEA. Nanomolar concentrations of AEA and the synthetic agonists CP 55 940 and JWH015 stimulated human osteoclast polarization and resorption; these effects were attenuated in the presence of CB(1) and/or CB(2) antagonists. CONCLUSIONS: AND IMPLICATIONS Low concentrations of cannabinoids activate human osteoclasts in vitro. There is a dynamic regulation of the expression of the CB(2) receptor and the production of the endocannabinoids during the differentiation of human bone cells. These data suggest that small molecules modulating the endocannabinoid system could be important therapeutics in human bone disease. LINKED ARTICLES: This article is part of a themed section on Cannabinoids in Biology and Medicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2012.165.issue-8. To view Part I of Cannabinoids in Biology and Medicine visit http://dx.doi.org/10.1111/bph.2011.163.issue-7. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/21649637/Cannabinoids_and_bone:_endocannabinoids_modulate_human_osteoclast_function_in_vitro_ L2 - https://doi.org/10.1111/j.1476-5381.2011.01519.x DB - PRIME DP - Unbound Medicine ER -